Paul Stoffels, Galapagos CEO (Michael Kovac/Getty Images)
June 21, 2022 04:01 PM EDTUpdated June 22, 10:54 AM
Deals

Gala­pa­gos CEO Paul Stof­fels bets €225M on a new CAR-T strat­e­gy for the long suf­fer­ing biotech

John Carroll

Editor & Founder

Tyler Patchen

News Reporter

The deeply trou­bled Eu­ro­pean biotech Gala­pa­gos and its new CEO Paul Stof­fels are go­ing the CAR-T route, and they have a new, €225 mil­lion buy­out …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Dan­ish biotech Gubra touts ear­ly weight loss da­ta in hot amylin field

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times